Innovative Digital Platform Aparito’s flagship Atom5™ eCOA platform utilizes advanced technology such as video assessments, wearable devices, and ePROs to facilitate patient-centric clinical trials, presenting opportunities to enhance digital health solutions and remote monitoring services for healthcare providers and biotech firms.
Recognition and Awards Being recognized as Digital Health Innovators of the Year and receiving awards like the EURORDIS Company Award positions Aparito as a credible partner for collaborations or investments from organizations seeking innovative health technology solutions.
Strategic Partnerships Collaborations with universities, hospitals, and international organizations like the Red Cross demonstrate Aparito’s ability to expand its reach and develop tailored solutions for diverse healthcare settings, opening avenues for joint ventures or pilot projects.
Research & Development Focus Aparito’s active involvement in R&D activities, including recent finalist positions in STEM innovation categories, indicates a strong commitment to developing cutting-edge healthcare technology, creating opportunities for co-development or licensing of new digital health tools.
Market Growth Potential With a revenue range of 1M to 10M and recent financial backing, coupled with a focus on real-world data collection and remote patient monitoring, Aparito is well-positioned for expansion into global clinical trial markets and digital health solutions for life-limiting diseases.
Aparito - a wholly owned subsidiary of Eli Lilly and Company uses 8 technology products and services including Open Graph, Neo4j, oEmbed, and more. Explore Aparito - a wholly owned subsidiary of Eli Lilly and Company's tech stack below.
| Aparito - a wholly owned subsidiary of Eli Lilly and Company Email Formats | Percentage |
| First.Last@aparito.com | 40% |
| First@aparito.com | 10% |
| First.Last@aparito.com | 40% |
| First@aparito.com | 10% |
Hospitals and Health CareWales, United Kingdom11-50 Employees
Aparito’s mission is to digitise clinical trials and accelerate drug development for patients with life-limiting diseases by supporting patient-centric clinical trials. We do this through our Atom5™ eCOA platform using video assessments, wearable devices and ePROs to generate continuous real-world data.
Company Overview
Media & News
Funding & FinancialsAparito - a wholly owned subsidiary of Eli Lilly and Company has raised a total of $1.3M of funding over 4 rounds. Their latest funding round was raised on Mar 01, 2019 in the amount of $1.3M.
Aparito - a wholly owned subsidiary of Eli Lilly and Company's revenue is estimated to be in the range of $1M$10M
Funding & FinancialsAparito - a wholly owned subsidiary of Eli Lilly and Company has raised a total of $1.3M of funding over 4 rounds. Their latest funding round was raised on Mar 01, 2019 in the amount of $1.3M.
Aparito - a wholly owned subsidiary of Eli Lilly and Company's revenue is estimated to be in the range of $1M$10M
1-888-653-2347 
support@leadiq.com